Pharmaceutical giant Merck announced mixed third-quarter results Friday, but lifted the lower end of its 2010 earnings guidance. Net income for the third quarter was $342 million, or 11 cents per share, as earnings were impacted by a large charge.
The Feds -- and consumers -- may finally have had it with 'pay-for-delay.' In these deals, generic drug companies that challenge a patent held by a name-brand pharmaceuticals agree to settle by delaying their entry into the market in return for a payment. But regulators are now calling for laws to end the practice.